U.S. stock night market fluctuations: PharmaCyte Biotech rose 9.09% in the night market, with active capital flow attracting market attention

U.S. Stock Night Market Movements

PharmaCyte Biotech rose 9.09% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Recursion fell 0.41% in the night market. Based on recent key news:

1. On December 5, Blake Borgeson, a director of Recursion Pharmaceuticals, reported the sale of company common stock. This move may raise concerns in the market about insider confidence in the company, affecting the stock price.

2. On December 3, Blake Borgeson submitted Form 144, planning to sell 220,000 shares of restricted securities. Such transactions typically trigger investor attention on the company's future performance, leading to stock price fluctuations.

3. On December 2, Blake Borgeson sold 220,000 shares at a price of $4.37 per share, totaling $961,400. This transaction raised concerns in the market about an increase in the supply of the company's stock, affecting the stock price. The U.S. stock market has seen increased volatility recently, and risks should be monitored.

Kala Pharmaceuticals rose 8.92% in the night market. Based on recent key news:

1. On December 5, Kala Bio announced a direct offering of 10 million shares at a price of $1.00 per share, with expected total proceeds of approximately $10 million. This move aims to repay debt and for general corporate purposes, driving the stock price up. Source: Company announcement

2. On December 4, Kala Bio appointed David Lazar as CEO, who previously served as CEO of NovaBay Pharmaceuticals. This leadership change may enhance market confidence in the company's future development. Source: Benzinga

3. On December 3, Kala Bio submitted a beneficial ownership statement to the U.S. Securities and Exchange Commission, confirming Oxford Finance LLC as the beneficial owner. This disclosure may affect investors' views on the company's equity structure. Source: EDGAR system. The biopharmaceutical industry has seen significant fluctuations recently, and attention is needed.

Capricor Therapeutics had a trading volume of $40,100. Based on recent key news:

1. On December 3, Capricor's experimental cell therapy successfully slowed the progression of Duchenne muscular dystrophy in late-stage trials, with the stock price soaring 371%. The therapy helps patients maintain heart function, pushing the stock price to an eight-year high. Source: Reuters

2. On December 4, Capricor announced the launch of a public stock offering, planning to use the raised funds to continue the development and production of its product candidates. The stock price rose 2.6% in after-hours trading. Source: MT Newswires On December 4th, analyst Joseph Pantginis reiterated a buy rating and raised the target price to $60, reflecting the market's optimistic expectations for Capricor. Source: H.C. Wainwright. The biotechnology sector has performed strongly recently, with significant capital inflows